Rain Oncology Inc (NASDAQ:RAIN) announced topline Phase 3 MANTRA data of milademetan in patients with dedifferentiated (DD) liposarcoma (LPS).
The study did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review compared to the standard of care, Johnson & Johnson's (NYSE:JNJ) Yondelis (trabectedin).
Related: Anticipation Builds For Rain Oncology's Phase 3 MANTRA Trial Results, Analyst Sees Promise.
The median PFS for milademetan was 3.6 months vs. 2.2 months for trabectedin, with a hazard ratio of 0.89, p=0.53.
The most common treatment-emergent adverse events (TEAEs) in the milademetan arm included nausea, thrombocytopenia, anemia, vomiting, and neutropenia.
The most common Grade 3/4 TEAEs were thrombocytopenia (39.5%), neutropenia (25.5%), and anemia (18.6%).
Dose reductions in the milademetan arm were 44.2% vs. 29.1% in the trabectedin arm.
Discontinuation in the milademetan arm due to AEs was 11.6% vs. 19.0% for trabectedin.
Based upon these topline data, Rain does not expect to pursue further development of milademetan in DD LPS.
Price Action: RAIN shares are down 86.9% at $1.30 on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
